Close Menu

NEW YORK — Serological tests for visceral leishmaniasis (VL) currently available in Brazil — a hotspot for the tropical disease — vary significantly in their performance, highlighting the need for more stringent validation before such diagnostics are released to the market, according to a new study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.